Cargando…

Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer

Early detection of ovarian cancer promises to reduce mortality. While serum CA125 can detect more than 60% of patients with early stage (I–II) disease, greater sensitivity might be observed with a panel of biomarkers. Ten protein antigens and 12 autoantibody biomarkers were measured in sera from 76...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Jing, Yang, Wei-Lei, Pak, Daewoo, Celestino, Joseph, Lu, Karen H., Ning, Jing, Lokshin, Anna E., Cheng, Zhongping, Lu, Zhen, Bast, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562667/
https://www.ncbi.nlm.nih.gov/pubmed/31035430
http://dx.doi.org/10.3390/cancers11050596
_version_ 1783426355039305728
author Guo, Jing
Yang, Wei-Lei
Pak, Daewoo
Celestino, Joseph
Lu, Karen H.
Ning, Jing
Lokshin, Anna E.
Cheng, Zhongping
Lu, Zhen
Bast, Robert C.
author_facet Guo, Jing
Yang, Wei-Lei
Pak, Daewoo
Celestino, Joseph
Lu, Karen H.
Ning, Jing
Lokshin, Anna E.
Cheng, Zhongping
Lu, Zhen
Bast, Robert C.
author_sort Guo, Jing
collection PubMed
description Early detection of ovarian cancer promises to reduce mortality. While serum CA125 can detect more than 60% of patients with early stage (I–II) disease, greater sensitivity might be observed with a panel of biomarkers. Ten protein antigens and 12 autoantibody biomarkers were measured in sera from 76 patients with early stage (I–II), 44 patients with late stage (III–IV) ovarian cancer and 200 healthy participants in the normal risk ovarian cancer screening study. A four-biomarker panel (CA125, osteopontin (OPN), macrophage inhibitory factor (MIF), and anti-IL-8 autoantibodies) detected 82% of early stage cancers compared to 65% with CA125 alone. In early stage subjects the area under the receiver operating characteristic curve (AUC) for the panel (0.985) was significantly greater (p < 0.001) than the AUC for CA125 alone (0.885). Assaying an independent validation set of sera from 71 early stage ovarian cancer patients, 45 late stage patients and 131 healthy women, AUC in early stage disease was improved from 0.947 with CA125 alone to 0.974 with the four-biomarker panel (p = 0.015). Consequently, OPN, MIF and IL-8 autoantibodies can be used in combination with CA125 to distinguish ovarian cancer patients from healthy controls with high sensitivity. Osteopontin appears to be a robust biomarker that deserves further evaluation in combination with CA125.
format Online
Article
Text
id pubmed-6562667
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65626672019-06-17 Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer Guo, Jing Yang, Wei-Lei Pak, Daewoo Celestino, Joseph Lu, Karen H. Ning, Jing Lokshin, Anna E. Cheng, Zhongping Lu, Zhen Bast, Robert C. Cancers (Basel) Article Early detection of ovarian cancer promises to reduce mortality. While serum CA125 can detect more than 60% of patients with early stage (I–II) disease, greater sensitivity might be observed with a panel of biomarkers. Ten protein antigens and 12 autoantibody biomarkers were measured in sera from 76 patients with early stage (I–II), 44 patients with late stage (III–IV) ovarian cancer and 200 healthy participants in the normal risk ovarian cancer screening study. A four-biomarker panel (CA125, osteopontin (OPN), macrophage inhibitory factor (MIF), and anti-IL-8 autoantibodies) detected 82% of early stage cancers compared to 65% with CA125 alone. In early stage subjects the area under the receiver operating characteristic curve (AUC) for the panel (0.985) was significantly greater (p < 0.001) than the AUC for CA125 alone (0.885). Assaying an independent validation set of sera from 71 early stage ovarian cancer patients, 45 late stage patients and 131 healthy women, AUC in early stage disease was improved from 0.947 with CA125 alone to 0.974 with the four-biomarker panel (p = 0.015). Consequently, OPN, MIF and IL-8 autoantibodies can be used in combination with CA125 to distinguish ovarian cancer patients from healthy controls with high sensitivity. Osteopontin appears to be a robust biomarker that deserves further evaluation in combination with CA125. MDPI 2019-04-28 /pmc/articles/PMC6562667/ /pubmed/31035430 http://dx.doi.org/10.3390/cancers11050596 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Guo, Jing
Yang, Wei-Lei
Pak, Daewoo
Celestino, Joseph
Lu, Karen H.
Ning, Jing
Lokshin, Anna E.
Cheng, Zhongping
Lu, Zhen
Bast, Robert C.
Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer
title Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer
title_full Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer
title_fullStr Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer
title_full_unstemmed Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer
title_short Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer
title_sort osteopontin, macrophage migration inhibitory factor and anti-interleukin-8 autoantibodies complement ca125 for detection of early stage ovarian cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562667/
https://www.ncbi.nlm.nih.gov/pubmed/31035430
http://dx.doi.org/10.3390/cancers11050596
work_keys_str_mv AT guojing osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer
AT yangweilei osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer
AT pakdaewoo osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer
AT celestinojoseph osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer
AT lukarenh osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer
AT ningjing osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer
AT lokshinannae osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer
AT chengzhongping osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer
AT luzhen osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer
AT bastrobertc osteopontinmacrophagemigrationinhibitoryfactorandantiinterleukin8autoantibodiescomplementca125fordetectionofearlystageovariancancer